| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Protagonist Therapeutics Inc (NASDAQ: PTGX)
PTGX Technical Analysis
5
| As on 1st Aug 2025 PTGX STOCK Price closed @ 53.83 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 36.50 & Strong Buy for SHORT-TERM with Stoploss of 28.16 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PTGXSTOCK Price
| Open | 54.01 | Change | Price | % |
| High | 55.49 | 1 Day | -0.03 | -0.06 |
| Low | 53.60 | 1 Week | -0.36 | -0.66 |
| Close | 53.83 | 1 Month | -0.09 | -0.17 |
| Volume | 600772 | 1 Year | 26.84 | 99.44 |
| 52 Week High 59.76 | 52 Week Low 24.66 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 173.72 | -2.33% |
| OPEN | 2.10 | 14.13% |
| EQ | 0.71 | 82.05% |
| AMZN | 214.75 | -8.27% |
| NCNA | 0.04 | 0.00% |
| LMDX | 0.02 | 0.00% |
| BTAI | 1.37 | 4.58% |
| AKTS | 0.04 | 0.00% |
| AAPL | 202.38 | -2.50% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| PTGX Daily Charts |
PTGX Intraday Charts |
Whats New @ Bazaartrend |
PTGX Free Analysis |
|
|
PTGX Important Levels Intraday
| RESISTANCE | 57.47 |
| RESISTANCE | 56.30 |
| RESISTANCE | 55.58 |
| RESISTANCE | 54.86 |
| SUPPORT | 52.80 |
| SUPPORT | 52.08 |
| SUPPORT | 51.36 |
| SUPPORT | 50.19 |
PTGX Forecast August 2025
| 4th UP Forecast | 67.49 |
| 3rd UP Forecast | 63.11 |
| 2nd UP Forecast | 60.4 |
| 1st UP Forecast | 57.69 |
| 1st DOWN Forecast | 49.97 |
| 2nd DOWN Forecast | 47.26 |
| 3rd DOWN Forecast | 44.55 |
| 4th DOWN Forecast | 40.17 |
PTGX Weekly Forecast
| 4th UP Forecast | 63.62 |
| 3rd UP Forecast | 60.48 |
| 2nd UP Forecast | 58.54 |
| 1st UP Forecast | 56.60 |
| 1st DOWN Forecast | 51.06 |
| 2nd DOWN Forecast | 49.12 |
| 3rd DOWN Forecast | 47.18 |
| 4th DOWN Forecast | 44.04 |
PTGX Forecast2025
| 4th UP Forecast | 123.93 |
| 3rd UP Forecast | 101.45 |
| 2nd UP Forecast | 87.55 |
| 1st UP Forecast | 73.66 |
| 1st DOWN Forecast | 34 |
| 2nd DOWN Forecast | 20.11 |
| 3rd DOWN Forecast | 6.21 |
| 4th DOWN Forecast | -16.27 |
Protagonist Therapeutics Inc ( NASDAQ USA Symbol : PTGX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PTGX Business Profile
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase II clinical trial for treating inflammatory bowel disease (IBD). The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis; and PN-235 and PN-232 oral interleukin-23 receptor antagonist candidates for IBD and non-IBD indications. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service